, Volume 3, Issue 2, pp 170–180 | Cite as

New generation anticonvulsants for the treatment of epilepsy in children

  • Elizabeth J. Donner
  • O. Carter Snead


In the last 12 years, 10 new anticonvulsants have been approved by the U.S. Food and Drug Administration and. as a result, the treatment options for children and adults with epilepsy have been expanded considerably. These new generation antiepileptic drugs offer equal efficacy with improved tolerability, pharmacokinetic properties, and side effect profiles compared with the traditional drugs. With many new medications available, the clinician treating children with epilepsy must be well versed in the application of these drugs to their patient population. This manuscript will review the indications, mechanism of action, pharmacokinetics, adverse effects, and dosing of the new generation of anticonvulsant medications.

Key Words

Antiepileptic drug (AED) anticonvulsant epilepsy children 


  1. 1.
    Chang BS, Lowenstein DH. Epilepsy.N Engl J Med 349: 1257–1266, 2003.PubMedCrossRefGoogle Scholar
  2. 2.
    Kwan P, Brodie MJ. Early identification of refractory epilepsy.N Engl J Med 342: 314–319, 2000.PubMedCrossRefGoogle Scholar
  3. 3.
    White HS. Animal models of epileptogenesis.Neurology 12 [Suppl 5]: S7-S14, 2002.CrossRefGoogle Scholar
  4. 4.
    Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of “chronic epilepsy”?Epilepsia 37: 701–708, 1996.PubMedCrossRefGoogle Scholar
  5. 5.
    Dodson WE. Pharmacokinetic principles of antiepileptic therapy in children. In: Pediatric epilepsy diagnosis and therapy (Pellock JM, Dodson WE, Bourgeois, BFD, eds), Vol 23, Ed 2, pp 317–327. New York: Demos Medical Publishing, 2001.Google Scholar
  6. 6.
    Dunn DW. Neuropsychiatric aspects of epilepsy in children.EpilepsyBehav 4: 101–106, 2003.Google Scholar
  7. 7.
    Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy.J Child Neurol 17 [Suppl 1]: S4-S17, 2002.PubMedCrossRefGoogle Scholar
  8. 8.
    Saint-Martin AD, Seegmuller C, Carcangiu R, Kleitz C, Hirsch E, Marescaux C, Metz-Lutz MN. Cognitive consequences of rolandic epilepsy.Epileptic Disord 2: S159-S165, 2001.Google Scholar
  9. 9.
    Camfield P, Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment.Epilepsia 43 [Suppl 3]: 27–32, 2002.PubMedCrossRefGoogle Scholar
  10. 10.
    Yung AW, Park YD, Cohen MJ, Garrison TN. Cognitive and behavioral problems in children with centrotemporal spikes.Pediatr Neurol 23: 391–395, 2000.PubMedCrossRefGoogle Scholar
  11. 11.
    Helmstaedter C, Kurthen M, Lux S, Reuber M, Elger CE. Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy.Ann Neurol 54: 425–432, 2003.PubMedCrossRefGoogle Scholar
  12. 12.
    Miller V, Palermo TM, Grewe SC. Quality of life in pediatric epilepsy: demographic and disease-related predictors and comparison with healthy controls.Epilepsy Behav 4: 36–42, 2003.PubMedCrossRefGoogle Scholar
  13. 13.
    Austin JK, Huster GA, Dunn D, Risinger MW. Adolescents with active or inactive epilepsy or asthma: a comparison of quality of life.Epilepsia 37: 1228–1238, 1996.PubMedCrossRefGoogle Scholar
  14. 14.
    Sillanpaa M, Jalava M, Kaleva O, et al. Long-term prognosis of seizures with onset in childhood.N Engl J Med 338: 1715–1722, 1998.PubMedCrossRefGoogle Scholar
  15. 15.
    Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology.Epilepsia 42: 796–803, 2001.PubMedCrossRefGoogle Scholar
  16. 16.
    Pellock JM. Felbamate.Epilepsia 40 [Suppl 5]: S57-S62, 1999.PubMedCrossRefGoogle Scholar
  17. 17.
    LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review.J Am Med Assoc 291: 605–614, 2004.CrossRefGoogle Scholar
  18. 18.
    Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).Epilepsy Res 61: 1–48, 2004.PubMedCrossRefGoogle Scholar
  19. 19.
    The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).N Engl J Med 328: 29–33, 1993.CrossRefGoogle Scholar
  20. 20.
    Carmant L, Holmes GL, Sawyer S, et al. Efficacy of felbamate in therapy for partial epilepsy in children.J Pediatr 125: 481–486, 1994.PubMedCrossRefGoogle Scholar
  21. 21.
    Leppik IE. Felbamate.Epilepsia 36 [Suppl 2]: S66-S72, 1995.PubMedCrossRefGoogle Scholar
  22. 22.
    Glauser TA, Graves NM. Phenytoin and fosphenytoin. In: The treatment of epilepsy: principles and practice (Wyllie E, ed), Vol 58, Ed 3, pp 853–868. Philadelphia: Lippincott Williams & Wilkins, 2001.Google Scholar
  23. 23.
    McLean MJ. Gabapentin. In: The treatment of epilepsy: principles and practice (Wyllie E, ed), Vol 62, Ed 3, pp 853–868. Philadelphia: Lippincott Williams & Wilkins, 2001.Google Scholar
  24. 24.
    Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicenter, double-blind, placebo controlled study.Epilepsia 40: 1147–1154, 1999.PubMedCrossRefGoogle Scholar
  25. 25.
    Shapiro DY, Nordli D, Glauser TA, Knapp LE, Greiner M, Purcell T, Brigell M, Fichtner K, Kugler AR, Malicsi M, Smith TM, Garofalo EA. Gabapentin as add-on therapy for refractory partial seizures in children 1–36 months of age: a novel short-term, placebo-controlled trial.Epilepsia 41 [Suppl 7]: 106, 2000.Google Scholar
  26. 26.
    Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progess report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).Epilepsy Res 51: 31–71, 2002.PubMedCrossRefGoogle Scholar
  27. 27.
    Bergin AM, Connolly M. New antiepileptic drug therapies.Neurol Clin N Am 20: 1163–1182, 2002.Google Scholar
  28. 28.
    Gilliam FG, Gidal, BE. Lamotrigine. In: The treatment of epilepsy: principles and practice (Wyllie E, ed), Vol 63, Ed 3, pp 853–868. Philadelphia: Lippincott Williams & Wilkins, 2001.Google Scholar
  29. 29.
    Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children.Neurology 53: 1724–1731, 1999.PubMedCrossRefGoogle Scholar
  30. 30.
    Eriksson A-S, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study.Epilepsia 39: 495–501, 1998.PubMedCrossRefGoogle Scholar
  31. 31.
    Motte J, Trevathan E, Arvidsson JFV, et al., The Lamictal Lennox-Gastaut Study Group. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome.N Engl J Med 337: 1807–1812, 1997.PubMedCrossRefGoogle Scholar
  32. 32.
    Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children.Epilepsia 40: 985–991, 1999.PubMedCrossRefGoogle Scholar
  33. 33.
    Yuen AWC, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism.Br J Clin Pharmacol 33: 511–513, 1992.PubMedCrossRefGoogle Scholar
  34. 34.
    Wong IC, Lahtoo SD. Adverse reactions to new anticonvulsant drugs.Drug Saf 23: 35–56, 2000.PubMedCrossRefGoogle Scholar
  35. 35.
    Beydoun A, Sachdeo RC, Kutluay E, et al. Sustained efficacy and long term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial seizures.Epilepsia 44: 1160–1165, 2003.PubMedCrossRefGoogle Scholar
  36. 36.
    Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy.Epilepsy Res 27: 205–213, 1997.PubMedCrossRefGoogle Scholar
  37. 37.
    Sillanpaa ML. Carbamazepine and Oxcarbazepine. In: The treatment of epilepsy: principles and practice (Wyllie E, ed), Vol 56, Ed 3, pp 853–868. Philadelphia: Lippincott Williams & Wilkins, 2001.Google Scholar
  38. 38.
    Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.Epilepsia 35: 181–188, 1994.PubMedCrossRefGoogle Scholar
  39. 39.
    Smith PEM. Clinical recommendations for oxcarbazepine.Scizure 10: 87–91, 2001.Google Scholar
  40. 40.
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice.Epilepsia 45 [Suppl 6]: 13–18, 2004.PubMedCrossRefGoogle Scholar
  41. 41.
    Brodie MJ. Pregabalin as adjunctive therapy for partial seizures.Epilepsia 45 [Suppl 6]: 19–27, 2004.PubMedCrossRefGoogle Scholar
  42. 42.
    Stratton SC, Large CH, Cox B, Davies G, Hagan RM. Effects of lamotrigine and levetiracetam on seizure-development in a rat amygdala kindling modelEpilepsy Res 53: 95–106, 2003.PubMedCrossRefGoogle Scholar
  43. 43.
    Lynch B, Lambeng N, Nocka K, Kensel-Hammes P, Bajjellieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.Proc Natl Acad Sci USA 10: 9861–9866, 2004.CrossRefGoogle Scholar
  44. 44.
    Bourgeois BFD, Holder DL, Valencia I, et al. Open label assessment of levetiracetam efficacy and adverse effects in a pediatric population.Epilepsia 42 [Suppl 7]: 253–254, 2001.Google Scholar
  45. 45.
    Glauser T, Bebin M, Ritter F, et al. Open-label efficacy and safety of levetiracetam in pediatric patients with partial-onset seizures (abstract).Epilepsia 40: 161, 1999.CrossRefGoogle Scholar
  46. 46.
    Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes.Eur J Pediatr Neurol 7: 123–128, 2003.CrossRefGoogle Scholar
  47. 47.
    Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy.Epilepsia 42: 1161–1163, 2001.Google Scholar
  48. 48.
    Shinnar S, Sommerville KW, Tiagabine. In: Pediatric epilepsy diagnosis and therapy (Pellock JM, Dodson WE, Bourgeois, BFD, eds), Vol 37, Ed 2, pp 489–498. New York: Demos Medical Publishing, 2001.Google Scholar
  49. 49.
    Eckardt KM, Steinhoff BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment.Epilepsia 39: 671–674, 1998.PubMedCrossRefGoogle Scholar
  50. 50.
    Ettinger AB, Bernai OG, Andriola MR, Bagchi S, et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy.Epilepsia 40: 1159–1162, 1999.PubMedCrossRefGoogle Scholar
  51. 51.
    Snead OC, Depaulis A, Vergnes M, Marescaux C. Absence epilepsy: advances in experimental animal models.Adv Neurol 79: 253–278, 1999.PubMedGoogle Scholar
  52. 52.
    Shinnar S, Berg AT, Treiman DM, Hauser WA, Hesdorffer DC, Scakellares JC, Leppik I, Sillanpaa M, Sommerville KW. Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons.Epilepsia 42: 372–379, 2001.PubMedCrossRefGoogle Scholar
  53. 53.
    Krauss GL, Johnson MA, Sheth S, Miller NR. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.J Neurol Neurosurg Psychiatry 74: 339–343, 2003.PubMedCrossRefGoogle Scholar
  54. 54.
    Kalviainen R, Hache JC, Renault-Dijouadi JA. A study of visual fields in patients receiving tiagabine as monotherapy versus carbamazepine or lamotrigine monotherapy.Epilepsia 42 [Suppl 7]: 256, 2001.Google Scholar
  55. 55.
    Schachter SC. Tiagabine. In: The treatment of epilepsy: principles and practice (Wyllie E, ed), Vol 65, Ed 3, pp 853–868. Philadelphia: Lippincott Williams & Wilkins, 2001.Google Scholar
  56. 56.
    DeLorenzo RJ, Sombati S, Coulter DA, et al. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons.Epilepsia 41 [Suppl 1]: S40-S44, 2000.PubMedCrossRefGoogle Scholar
  57. 57.
    Gibbs JW III, Sombati S, Delorenzo RJ, et al. Cellular actions of topiramate: blockade of kainite-evoked inward currents in cultured hippocampal neurons.Epilepsia 41 [Suppl]: 510–516, 2000.CrossRefGoogle Scholar
  58. 58.
    White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold.Epilepsy Res 28: 167–179, 1997.PubMedCrossRefGoogle Scholar
  59. 59.
    Qian J, Noebels JL. Topiramate alters excitatory synaptic transmission in mouse hippocampus.Epilepsy Res 55: 225–233, 2003.PubMedCrossRefGoogle Scholar
  60. 60.
    Russo E, Constanti A. Topiramate hyperpolarizes and modulates the slow poststimulus AAHP of rat olfactory cortical neurons in vitro.Br J Pharmacol 1441: 285–301, 2004.CrossRefGoogle Scholar
  61. 61.
    Gryder DS, Rogawski MA. Selective antagonism of gluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons.J Neurosci 23: 7069–7074, 2003.PubMedGoogle Scholar
  62. 62.
    Angehagen M, Ben-Menachem E, Shank R, Ronback L, Hanson E. Topiramate modulation of kainite-induced calcium currents is inversely related to channel phosphorylation level.J Neurochem 88: 320–356, 2004.PubMedCrossRefGoogle Scholar
  63. 63.
    Elterman RD, Glauser TA, Wyllie E, et al, and the Topiramate YP Study Group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children.Neurology 52: 1338–1344, 1999.PubMedCrossRefGoogle Scholar
  64. 64.
    Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms.Epilepsia 39: 1324–1328, 1998.PubMedCrossRefGoogle Scholar
  65. 65.
    Glauser TA. Topiramate in the catastrophic epilepsies of childhood.J Child Neurol 15 [Suppl 1]: S14-S21, 2000.PubMedCrossRefGoogle Scholar
  66. 66.
    Sachdeo RC, Glauser TA, Ritter F, et al, and the Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome.Neurology 52: 1882–1887, 1999.PubMedCrossRefGoogle Scholar
  67. 67.
    Grosso S, Galimberti D, Fametani MA, Cioni M, Mostardini R, Vivarelli R, Di Bartolo RM, Bemardoni E, Berardi R, Morgese G, Balestri P. Efficacy and safety of topiramate in infants according to epilepsy syndromes.Scizure 14: 183–189, 2005.CrossRefGoogle Scholar
  68. 68.
    Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data.Clin Pharmacokinet 44: 407–416, 2005.PubMedCrossRefGoogle Scholar
  69. 69.
    Hammoudi DS, Lee SSF, Madison A, et al. Reduced visual function associated with infantile spasms in children on vigabatrin therapy.Invest Ophthamol Visual Sci 46: 514–520, 2005.CrossRefGoogle Scholar
  70. 70.
    Mackay MT, Weiss SK, Actams-Webber T, et al. Practice parameter: medical treatment of infantile spasms.Neurology 62: 1668–1681, 2004.PubMedCrossRefGoogle Scholar
  71. 71.
    Curatolo P, Verdecchia M, Bombardieri R. Vigabatrin for tuberous sclerosis complex.Brain Dev 23: 649–653, 2001.PubMedCrossRefGoogle Scholar
  72. 72.
    Westall CA, Logan WJ, Smith K, Buncic JR, Panton CM, Abdolell M, The Hospital for Sick Children, Toronto. Longitudinal ERG study of children on vigabatrin.Doc Ophthalmol 104:133-149, sofaction.Google Scholar
  73. 73.
    Macdonald RL, Duche B. Zonisamide: mechanisms of action. In: Antiepileptic drugs. (Levy RH, Mattson RH, Meldrum BS, Perucca E, eds), Ed 5, pp 867–872. Philadelphia: Lippincott, Williams & Wilkins, 2002.Google Scholar
  74. 74.
    Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebocontrolled study in patients with refractory partial seizures.Epilepsia 46: 31–41, 2005.Google Scholar
  75. 75.
    Fisher RS, Kerrigan JF III, Pellock JM. Zonisamide. In: Pediatric epilepsy diagnosis and therapy, (Pellock JM, Dodson WE, Bourgeois, BFD, eds), Vol 39, Ed 2, pp 509–512. New York: Demos Medical Publishing, 2001.Google Scholar
  76. 76.
    Beghi, E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines.Lancet Neurol 3: 618–621, 2004.PubMedCrossRefGoogle Scholar
  77. 77.
    Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs.Nat Rev Neurosci 5: 553–564, 2004.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2006

Authors and Affiliations

  1. 1.Division of Neurology and Program in Brain and Behavior, Hospital for Sick Children, Department of Pediatrics, Faculty of MedicineUniversity of TorontoTorontoCanada
  2. 2.Division of NeurologyThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations